Search

• 

  Tony Wood

  Company

  Tony was appointed Chief Scientific Officer designate on 19 January 2022 and became Chief Scientific Officer on 1 August 2022.

  https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/tony-wood/

  First published: 12 July 2024

• GSK signs agreement with the WHO to donate 50 million doses of pandemic H1N1 vaccine for distribution to developing countries

  Media

  GSK today announced that it has signed an agreement with WHO to donate 50 million doses of its influenza vaccine.

  https://www.gsk.com/en-gb/media/press-releases/gsk-signs-agreement-with-the-who-to-donate-50-million-doses-of-pandemic-h1n1-vaccine-for-distribution-to-developing-countries/

  First published: 09 November 2009

• ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months

  Media

  ATLAS-2M study met its primary endpoint.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-reports-positive-phase-iii-study-results-of-investigational-long-acting-injectable-hiv-treatment-regimen-administered-every-two-months/

  First published: 22 August 2019

• GSK receives US FDA Fast Track designation for bepirovirsen in chronic hepatitis B

  Media

  Designation underscores the unmet need for medicines that can achieve functional cure in patients with chronic hepatitis B (CHB)

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-fda-fast-track-designation-for-bepirovirsen-in-chronic-hepatitis-b/

  First published: 12 February 2024

• Shionogi-ViiV Healthcare announces initial data from pivotal phase III study of dolutegravir in HIV

  Media

  SPRING-2 study meets primary endpoint of non-inferiority of dolutegravir compared to raltegravir over 48 weeks in treatment of HIV patients.

  https://www.gsk.com/en-gb/media/press-releases/shionogi-viiv-healthcare-announces-initial-data-from-pivotal-phase-iii-study-of-dolutegravir-in-hiv/

  First published: 02 April 2012

• ViiV Healthcare starts third phase III HIV treatment study investigating long-acting two-drug regimen of cabotegravir plus rilpivirine

  Media

  ViiV announced start of phase III study with a two-drug regimen of long-acting, injectable cabotegravir & rilpivirine in adults with HIV-1.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-starts-third-phase-iii-hiv-treatment-study-investigating-long-acting-two-drug-regimen-of-cabotegravir-plus-rilpivirine/

  First published: 27 November 2017

• ViiV Healthcare launches eighth phase III study in two-drug regimen programme for HIV-1 treatment

  Media

  TANGO will seek to enrol approximately 550 adults with HIV-1, from clinical trial sites in North America, Europe, Australia, and Japan.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-launches-eighth-phase-iii-study-in-two-drug-regimen-programme-for-hiv-1-treatment/

  First published: 08 February 2018

• ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb” with potential for long-acting HIV treatment and prevention

  Media

  ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb”.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-exclusive-licensing-agreement-with-the-national-institutes-of-health-for-investigational-bnab-with-potential-for-long-acting-hiv-treatment-and-prevention/

  First published: 21 November 2019

• ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naïve Adults with HIV-1

  Media

  ViiV Healthcare today announced initial results from the Phase IIIb/IV FLAMINGO (ING114915) study.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-data-from-phase-iiibiv-study-of-dolutegravir-vs-darunavir-in-treatment-naïve-adults-with-hiv-1/

  First published: 12 September 2013

• ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing

  Media

  ViiV Healthcare presents positive 48-week data from phase III study

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-48-week-data-from-phase-iii-study-showing-every-two-month-regimen-of-investigational-long-acting/

  First published: 09 March 2020